ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer

FEBS Letters

Volumn 589, Issue 17, 2015, Pages 2248-2256

  Zhang, Pei ^a   Yu, Shuwen ^a   Li, Hongyu ^a   Liu, Chuanyong ^a   Li, Juan ^a   Lin, Wenli ^a   Gao, Aiqin ^a   Wang, Linlin ^a   Gao, Wei ^a   Sun, Yuping ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

B7 H3; ILT4; Non small cell lung cancer; PI3K AKT mTOR signalling

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; B7 H3 PROTEIN; CELL PROTEIN; IMMUNOGLOBULIN LIKE TRANSCRIPT 4 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LILRB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

B7 ANTIGENS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84938206585     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2015.06.037     Document Type: Article

References (41)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. S.S. Devesa, F. Bray, A.P. Vizcaino, and D.M. Parkin International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising Int. J. Cancer 117 2005 294 299
3. R. Siegel, and et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J. Clin. 62 2012 220 241
4. P. Vineis, and C.P. Wild Global cancer patterns: causes and prevention Lancet 383 2014 549 557
5. M. Colonna, H. Nakajima, and M. Cella A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells Semin. Immunol. 12 2000 121 127
6. V. Ristich, W. Zhang, S. Liang, and A. Horuzsko Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells Hum. Immunol. 68 2007 264 271
7. M. Shiroishi, and et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G Proc. Natl. Acad. Sci. U.S.A. 100 2003 8856 8861
8. A.I. Colovai, and et al. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia Cytometry B Clin. Cytometry 72 2007 354 362
9. J. Liu, and et al. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10 Diagn. Pathol. 9 2014 85
10. Y. Sun, J. Liu, P. Gao, Y. Wang, and C. Liu Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer Chest 134 2008 783 788
11. J. Zheng, and et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development Nature 485 2012 656 660
12. S. Ceeraz, E.C. Nowak, and R.J. Noelle B7 family checkpoint regulators in immune regulation and disease Trends Immunol. 34 2013 556 563
13. B. Seliger, and D. Quandt The expression, function, and clinical relevance of B7 family members in cancer Cancer Immunol. Immunother. 61 2012 1327 1341
14. S.J. Lee, and et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274) FEBS Lett. 580 2006 755 762
15. C. Chen, Y. Shen, Q.X. Qu, X.Q. Chen, X.G. Zhang, and J.A. Huang Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response Exp. Cell Res. 319 2013 96 102
16. J. Sun, Y. Mao, Y.Q. Zhang, Y.D. Guo, C.Y. Mu, F.Q. Fu, and X.G. Zhang Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer Oncol. Lett. 6 2013 1253 1260
17. Xu YH, Z.G., Wang JM, Hu HC. (2010 Sep). B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 31, 980-6.
18. G. Zhang, Y. Xu, X. Lu, H. Huang, Y. Zhou, B. Lu, and X. Zhang Diagnosis value of serum B7-H3 expression in non-small cell lung cancer Lung Cancer 66 2009 245 249
19. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
20. K.Y. Jun Konishi, Miyuki. Azuma, Ichiro. Kinoshita, Hirotoshi. Dosaka-Akita, and Masaharu Nishimura1 B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin. Cancer Res. 10 2004 7
21. A. Castellaneta, G.V. Mazariegos, N. Nayyar, A. Zeevi, and A.W. Thomson HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance Transplantation 91 2011 1132 1140
22. M. Loos, D.M. Hedderich, H. Friess, and J. Kleeff B7-H3 and its role in antitumor immunity Clin. Dev. Immunol. 2010 2010 683875
23. L. Wang, F.B. Kang, and B.E. Shan B7-H3-mediated tumor immunology: friend or foe? Int. J. Cancer 134 2014 2764 2771
24. D. Loo, and et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity Clin. Cancer Res. 18 2012 3834 3845
25. T.J. Roth, and et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy Cancer Res. 67 2007 7893 7900
26. H.Y. Yang, M. Chu, L.W. Zheng, R.A. Zwahlen, J. Luo, D.H. Zou, and S.T. Sun Transgenic B7-H3 therapy induces tumor-specific immune response in human oral squamous cell cancer: an in vitro study Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endodontol. 106 2008 721 728
27. X. Zang, and J.P. Allison The B7 family and cancer therapy: costimulation and coinhibition Clin. Cancer Res. 13 2007 5271 5279
28. Y. Sun, Y. Wang, J. Zhao, M. Gu, R. Giscombe, A.K. Lefvert, and X. Wang B7-H3 and B7-H4 expression in non-small-cell lung cancer Lung Cancer 53 2006 143 151
29. A. Kataki, P. Scheid, M. Piet, B. Marie, N. Martinet, Y. Martinet, and J.M. Vignaud Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression J. Lab. Clin. Med. 140 2002 320 328
30. A. Kilic, R.J. Landreneau, J.D. Luketich, A. Pennathur, and M.J. Schuchert Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors J. Surg. Res. 167 2011 207 210
31. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat. Rev. Cancer 9 2009 550 562
32. C. Fumarola, M.A. Bonelli, P.G. Petronini, and R.R. Alfieri Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer Biochem. Pharmacol. 2014
33. T.R. Kim, E.W. Cho, S.G. Paik, and I.G. Kim Hypoxia-induced SM22alpha in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy FEBS Lett. 586 2012 303 309
34. M. Atefi, and et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma Clin. Cancer Res. 20 2014 3446 3457
35. X. Jiang, J. Zhou, A. Giobbie-Hurder, J. Wargo, and F.S. Hodi The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition Clin. Cancer Res. 19 2013 598 609
36. A.T. Parsa, and et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat. Med. 13 2007 84 88
37. Y. Cheng, Y. Li, D. Liu, R. Zhang, and J. Zhang MiR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway FEBS Lett. 588 2014 3274 3281
38. M.K. Nygren, and et al. Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c Br. J. Cancer 110 2014 2072 2080
39. C. Tekle, M.K. Nygren, Y.W. Chen, I. Dybsjord, J.M. Nesland, G.M. Maelandsmo, and O. Fodstad B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes Int. J. Cancer 130 2012 2282 2290
40. J. Wang, and et al. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma J. Invest. Dermatol. 133 2013 2050 2058
41. X. Zhao, and et al. B7-H3 overexpression in pancreatic cancer promotes tumor progression Int. J. Mol. Med. 31 2013 283 291